June

"The Molecule We Thought We Knew"

CHAPTER 1:

"Everything Looked Perfect"

Early-stage data often tells only part of the story.

For biologics, subtle molecular differences can have significant downstream consequences.

Without deep characterization, critical attributes may remain invisible until much later in development.

CHAPTER 2:

"The Variant We Didn't Expect"

Biologics are inherently complex.

Charge variants, glycoforms, oxidation, deamidation, and other modifications can influence efficacy, safety, and stability.

Detecting them early can prevent costly surprises later.

CHAPTER 3:

"The Stability Question"

Stability is more than a shelf-life question.

It's a patient safety question.

Understanding degradation pathways early enables informed development decisions and reduces risk during scale-up.

CHAPTER 4:

"The Comparability Challenge"

Manufacturing changes can alter product attributes in unexpected ways.

Comparability studies require robust, reproducible analytical evidence to demonstrate product consistency.

FINAL CHAPTER:

"The Question We Should Have Asked Earlier"

Successful biologics development depends on making informed decisions early.

The deeper the analytical insight, the greater the confidence in development, manufacturing, and regulatory submissions.